필라나 테라퓨틱스FLNA 주가

Maxim Group Reinstates Buy on Filana Therapeutics, Announces $5 Price Target

Maxim Group analyst Jason McCarthy reinstates Filana Therapeutics (NASDAQ:FLNA) with a Buy and announces $5 price target.

Filana Therapeutics : Corporate Presentation May 2026

Investor Overview May 2026 Building on Simufilam Data to Pursue Development in a New Indication, Tuberous Sclerosis Complex -Related...

Filana Therapeutics Q1 EPS $(0.21) Beats $(0.23) Estimate

Filana Therapeutics (NASDAQ:FLNA) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.23) by 8.7 percent. This is a 56.25 percent increase over losses of $(0.48) per share from

Filana Therapeutics Reports Q1 2026 Financial Results and Business Update

AUSTIN, Texas, May 07, 2026 -- Filana Therapeutics, Inc. , a biotechnology company currently focused on developing therapies for Tuberous Sclerosis Complex -related epilepsy, today reported...

[8-K] 중대 사건 — FORM 8-K

[10-Q] 분기 실적 — FORM 10-Q

Filana Therapeutics Presents TSC-Related Epilepsy Program at Eilat XVIII

Presentation described the biological rationale for the evaluation of simufilam in TSC-related epilepsyAUSTIN, Texas, May 05, 2026 -- Filana Therapeutics, Inc. , a biotechnology company currently...

[ARS] ARS — FORM ARS

[DEF 14A] 주주총회 위임장 — FORM DEF 14A

[8-K] 중대 사건 — FORM 8-K